Latest Breaking News On - Sagimet biosciences inc - Page 2 : comparemela.com

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase

SAN MATEO, Calif., May 16, 2024 (GLOBE NEWSWIRE) Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional

Comunidad autonoma de catalunaUnited statesJoyce allaireScottl friedmanSagimet biosciencesMoshe orenAlpha omega honor societyWeizmann institute of scienceInternational hans popper awardExchange commissionHarvard medical schoolAmerican liver foundationAmerican college of physiciansFalk foundation in freiburgSagimet biosciences incAmerican gastroenterological association

Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesPaul hoelscherJoyce allaireDavid happelTim walbertSagimet biosciencesDrug administrationSagimet biosciences incExchange commissionInternational liver congressDenifanstat phaseLiver congressChief executive officerThree months ended marchPrivate securities litigation reform actMonths ended march

Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer

SAN MATEO, Calif., May 06, 2024 Sagimet Biosciences Inc. , a clinical-stage biopharmaceutical company developing novel fatty acid synthase inhibitors designed to target dysfunctional metabolic.

Pays de la loireFranche comtérUnited statesFrance generalDave happelSagimet biosciencesRothschild ciePonts paristechProvention bioJoyce allaireCompensation committeeWharton schoolSagimet biosciences incCompany seriesExchange commissionUniversity of pennsylvania

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024

Sagimet announced positive topline data from its FASCINATE-2 Phase 2b clinical trial of denifanstat in MASH in January 2024 and plans to initiate Phase 3 trial in the second half of 2024SAN MATEO,.

Brooke army medical centerUnited statesSan antonioJoyce allaireSagimet biosciencesStephen harrisonSaint louis universityExchange commissionSummit clinical researchUniversity of oxfordArmy surgeon generalUniformed services university of the health sciencesUnited states armySagimet biosciences incUniversity of mississippi school medicinePinnacle clinical research

Brokerages Set Sagimet Biosciences Inc (NASDAQ:SGMT) PT at $41 50

Brokerages Set Sagimet Biosciences Inc (NASDAQ:SGMT) PT at $41 50
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesDavid happelLeerink partnrsSagimet biosciencesBarclays plcSagimet biosciences company profileGoldman sachs groupSagimet biosciences incYork state common retirement fundVirtu financialGet free reportMarketbeat ratingsGet freeBiosciences incSagimet biosciences daily